Citius Pharmaceuticals Inc. Common Stock (CTXR)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunt, and Citius fails the first test: earning power. The company has an FDA-approved product, LYMPHIR, for cutaneous T-cell lymphoma, plus pipeline assets Mino-Lok and Halo-Lido. That is a real asset, but the commercial base is tiny, and I see no evidence of a durable competitive moat. In fiscal Q3 2026, the quarter ended 2026-06-30, revenue was $1.5 million and net income was negative $11.9 million, or diluted EPS of negative $0.34. Fiscal Q2 2026, ended 2026-03-31, showed revenue of $1.7 million and a net loss of $28.1 million. Fiscal Q1 2026, ended 2025-12-31, had revenue of $3.9 million and a net loss of $9.4 million. Annual losses have been persistent: FY2025 net income was negative $39.7 million, FY2024 negative $39.4 million, and FY2023 negative $32.5 million. The computed Lynch category is none because of losses in each of the last four years. Financial health is poor. Trailing free cash flow was negative $34.9 million, a FairStock FCF yield of negative 266.8% on a $13.1 million market cap at the 2026-10-13 close. The FairStock-calculated Altman Z-score is negative 2.90, and Piotroski is 3/9. The one bright spot is low leverage: D/E 0.09. Valuation looks cheap only on book: FairStock P/B is 0.20, while P/E is negative 0.27. But a low price relative to book is not a margin of safety if losses consume that book value. The 52-week range of $0.46 to $2.19 places the $0.48 price near the low. Without a credible path to profitability or a much larger revenue base, this is speculation, not a durable value investment.

In plain English: Citius Pharmaceuticals is a small biotech company with an FDA-approved cancer therapy called LYMPHIR and two other products in development. The business looks weak today because it is losing millions of dollars and burning cash, even though it has some sales. The share price is very low compared with the company's stated accounting value, but because the company is unprofitable, that low price may not be a true bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer